A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
Mesonephric Gynecologic Cancer
DRUG: Avutometinib (VS-6766)|DRUG: Defactinib
best overall response, as determined by RECIST 1.1, 2 years
Incidence and severity of adverse events, will be collected at each visit and tabulated with grading by CTCAE Version 5 criteria., 2 years
This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.